Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing | Companies to develop integration strategies for Fresenius Kabi's portfolio of Cell Therapy Technologies within Cellular Origins' Constellation automation platform Initial research to focus... ► Artikel lesen |
JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius vor Zahlen zum dritten Quartal auf "Overweight" mit einem Kursziel von 40,10 Euro belassen. Analyst David Adlington... ► Artikel lesen |
Fresenius SE Aktie: Kursgewinne und Zukunftsaussichten im Fokus | Die Fresenius SE-Aktie verzeichnete am jüngsten Handelstag einen leichten Kursanstieg von 0,4 Prozent und notierte bei 33,81 EUR. Im Tagesverlauf erreichte das Wertpapier ein Hoch von 34,04 EUR, was... ► Artikel lesen |
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in... ► Artikel lesen |
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation Therapy | SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
PROCEPT BioRobotics Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance | SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
Alignment Healthcare Reports First Quarter 2024 Results | Reports $628.6 million in total revenue and $627.6 million in revenue excluding ACO REACH, up 43.1% and 54.2% year-over-year respectivelyMedicare Advantage membership grows 50.5% year-over-year to... ► Artikel lesen |